Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × efgartigimod alfa × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

pembrolizumab 79 Carboplatin 65 Cisplatin 60 Paclitaxel 52 Specimen Handling 50 Magnetic Resonance Spectroscopy 48 Gemcitabine 46 Docetaxel 36 Cyclophosphamide 35 Pemetrexed 32 Dexamethasone 31 Doxorubicin 30 Fluorouracil 29 Bevacizumab 29 Radiotherapy 27 Capecitabine 27 durvalumab 26 Oxaliplatin 26 Rituximab 24 Radiation 24 Leucovorin 24 Vincristine 22 Lenalidomide 22 Nivolumab 18 Irinotecan 18 130-nm albumin-bound paclitaxel 18 venetoclax 17 Prednisone 17 Taxes 16 Letrozole 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07217587 2026-03-13

EPIC

Janssen Research & Development, LLC

Phase 3 Recruiting

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡